Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Abeona Therapeutics (ABEO) over the last 6 years, with Q3 2025 value amounting to $65.8 million.

  • Abeona Therapeutics' Shares Outstanding (Diluted Average) rose 3681.0% to $65.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.8 million, marking a year-over-year increase of 3681.0%. This contributed to the annual value of $41.0 million for FY2024, which is 9198.92% up from last year.
  • Latest data reveals that Abeona Therapeutics reported Shares Outstanding (Diluted Average) of $65.8 million as of Q3 2025, which was up 3681.0% from $66.6 million recorded in Q2 2025.
  • Abeona Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $66.6 million during Q2 2025, with a 5-year trough of $5.8 million in Q2 2022.
  • Its 4-year average for Shares Outstanding (Diluted Average) is $32.2 million, with a median of $26.1 million in 2023.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 28618.0% in 2023, then skyrocketed by 3008.96% in 2025.
  • Abeona Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $7.9 million in 2022, then skyrocketed by 171.96% to $21.4 million in 2023, then surged by 91.99% to $41.0 million in 2024, then skyrocketed by 60.25% to $65.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $65.8 million in Q3 2025, compared to $66.6 million in Q2 2025 and $49.8 million in Q1 2025.